Featured Research Search Results

Treating Advanced MSI-High or dMMR Cancers Using the Targeted Therapy MOMA-341 Given Alone or In Combination with Standard Therapies

Clinicaltrials.gov identifier:
NCT06974110

Treatment
Treatment study for people with advanced or metastatic cancers

Pfizer Clinical Trials for Metastatic Prostate Cancer are Now Enrolling

Treatment
Men aged 18 years or older with metastatic prostate cancer

Post-surgery Immunotherapy (Toripalimab) for MMR-D / MSI-H Stage IIB-III Colon Cancer

Clinicaltrials.gov identifier:
NCT07140679

Treatment
Study for people who have had surgery to remove the Stage IIB-III MMR-D / MSI-H colon cancer

Study of the Drug Olvi-Vec in Women with Ovarian Cancer

Clinicaltrials.gov identifier:
NCT05281471

Treatment
Treatment for women diagnosed with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer or whose cancer did not respond to prior chemotherapy

Effectiveness of Lymph Node Mapping to Reduce the Risk of Swelling in the Legs in Patients with Stage I Endometrial Cancer

Clinicaltrials.gov identifier:
NCT05646316

Treatment
People with stage I endometrial cancer who are having a hysterectomy

The Phoenix Trial: Cemiplimab for Patients with Localized dMMR Colon Cancer

Clinicaltrials.gov identifier:
NCT05961709

Treatment
Treatment study for people with localized colon cancer who have dMMR

Using ctDNA for Earlier Detection and Treatment of Recurrence or Spread after Treatment for Stage 3 Colon Cancer

Clinicaltrials.gov identifier:
NCT03803553

Treatment
Monitoring and treatment study for people who completed treatment for stage 3 colon cancer

Treatment of HER2-positive Colorectal Cancer as First Line Treatment in the Metastatic Setting

Clinicaltrials.gov identifier:
NCT05253651

Treatment
People with HER2-positive colorectal cancer who have not yet received treatment in the metastatic setting

Study of Colorectal Cancer and Genetics in Hispanic and Latino People (ENLACE Study)

Treatment
Hispanic and Latino people diagnosed with colorectal cancer

Nivolumab and Relatlimab in Advanced MSI-H Cancers Resistant to Prior PD-L1 Inhibitor

Clinicaltrials.gov identifier:
NCT03607890

Treatment
Solid tumors that are MSI-High and resistant to prior immunotherapy